Biology Reference
In-Depth Information
bepoetin alfa, which allow for reduced dosing frequency of the newer
agents?
The value of answering questions such as these would be in improving the
understanding between pharmacokinetics and pharmacodynamics with the
ultimate goal of optimizing and individualizing patient care.
Acknowledgements
Bhavna Thapar and Robert Rovetti assisted in the preparation of this manuscript.
References
1 Brockmöller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH (1992) The pharmacoki-
netics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.
Br
J Clin Pharmacol
34: 499-508
2 Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M (1992)
Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and mul-
tiple subcutaneous administrations.
Nephron
61: 393-398
3 Wide L, Bengtsson C, Birgegard G (1989) Circadian rhythm of erythropoietin in human serum.
Br J Haematol
72: 85-90
4 Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC (1998) Pharmacokinetics and pharmacody-
namics of recombinant human erythropoietin after single and multiple subcutaneous doses to
healthy subjects.
Clin Pharmacol Ther
64: 412-423
5 Schouten JP, Voorhorst G, Helbing AR, Janssen JW, Diderich PP, Op de Hoek CT (1993)
Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration:
Influence of chronic treatment.
Pharm World Sci
15:252-256
6 Gladziwa U, Klotz U, Baumer K, Zollinger R, Mann H, Sieberth HG (1993) Pharmacokinetics of
epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing
haemodialysis and haemofiltration.
Clin Pharmacokinet
25:145-153
7 Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA (1991)
Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.
Clin
Pharmacol Ther
50: 702-712
8Nielsen OJ (1990) Pharmacokinetics of recombinant human erythropoietin in chronic haemodial-
ysis patients.
Pharmacol Toxicol
66: 83-86
9 Salmonson T, Danielson BG, Grahnen A, Wikstrom B (1990) Pharmacokinetics of intravenous
recombinant human erythropoietin in patients with chronic renal failure.
J Intern Med
228: 53-57
10 Boelaert JR, Schurgers ML, Matthys EG, Belpaire FM, Daneels RF, De Cre MJ, Bogaert MG
(1989) Comparative pharmacokinetics of recombinant erythropoietin administered by the intra-
venous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis
(CAPD) patients.
Perit Dialy Int
9:95-98
11 Urabe A, Takaku F, Mizoguchi H, Kubo K, Ota K, Shimizu N, Tanaka K, Mimura N, Nihei H,
Koshikawa S (1988) Effect of recombinant human erythropoietin on the anemia of chronic renal
failure.
Int J Cell Cloning
6:179-191
12Cheung WK, Natarajan J, Sanders M, Vercammen E (2000) Comparative pharmacokinetics, safe-
ty, and tolerability after subcutaneous administration of recombinant human erythropoietin for-
mulated with different stabilizers.
Biopharm Drug Dispos
21: 211-219
13 Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW (1993)
Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythro-
poietin in patients on continuous ambulatory peritoneal dialysis.
Am J Kidney Dis
21: 635-642
14 Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH (1990)
Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy
men.
Clin Pharmacol Ther
47: 557-564
15 McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL (1990) Pharmacokinetics
and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in